Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse

被引：1
|
作者：
Benton, Christopher B. [1 ]
Konopleva, Marina
Saliba, Rima M.
Shpall, Elizabeth J.
Ciurea, Stefan O. [2 ]
Kebriaei, Partow [2 ]
Alousi, Amin M. [2 ]
Popat, Uday R. [2 ]
Anderlini, Paolo [2 ]
Nieto, Yago [2 ]
Parmar, Simrit
Zeng, Zhihong [3 ]
Chen, Julianne J.
Rondon, Gabriela [2 ]
McMullin, Becky
Wang, Rui-Yu
Lu, Hongbo [3 ]
Schober, Wendy D. [3 ]
Woodworth, Glenda G.
Gulbis, Alison [4 ]
Cool, Rita [4 ]
Qiao, Wei [5 ]
Thall, Peter F.
Andreeff, Michael
Champlin, Richard E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.360.360
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
360
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS
    Tang, XiaoWen
    De Lima, Marcos
    Wei, Wei
    Chiattone, Alexandre
    Thall, Peter F.
    Jeffrey, Medeiros
    Rondon, Gabriela
    Chen, Julianne J.
    Shpall, Elizabeth J.
    Jones, Roy
    Nieto, Yago
    Alousi, Amin M.
    Champlin, Richard E.
    Andersson, Borje S.
    BLOOD, 2010, 116 (21) : 1414 - 1414
  • [42] HEALTH ECONOMIC OUTCOME ANALYSIS OF STEM CELL MOBILIZATION WITH GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PLUS PLERIXAFOR VERSUS G-CSF ALONE IN PREPARATION FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMAS (NHL)
    Pusic, I
    Kymes, S. M.
    Lambert, D. L.
    Gregory, M.
    DiPersio, J. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S212 - S212
  • [43] A combination of idarubicin, fludarabine, Ara-C and G-CSF induction with or without consolidation using busulfan and cytoxan (BU/CY) plus peripheral blood stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) and acute myelogenous leukemia.
    Besa, EC
    Rousch, R
    Rovito, M
    BLOOD, 1997, 90 (10) : 4029 - 4029
  • [44] Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation
    Ye, Peipei
    Pei, Renzhi
    Jin, Jie
    Sun, Jie
    Li, Kongfei
    Cao, Junjie
    Zhou, Dandan
    Lu, Ying
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2073 - 2080
  • [45] Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation
    Peipei Ye
    Renzhi Pei
    Jie Jin
    Jie Sun
    Kongfei Li
    Junjie Cao
    Dandan Zhou
    Ying Lu
    Annals of Hematology, 2019, 98 : 2073 - 2080
  • [46] Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
    Rosenow, Felix
    Silling, Gerda
    Almut, Berkemeier
    Mueller-Tidow, Carsten
    Koschmieder, Steffen
    Bisping, Guido
    Krug, Utz
    Buechner, Thomas
    Berdel, Wolfgang E.
    Kienast, Joachim
    Stelljes, Matthias
    BLOOD, 2009, 114 (22) : 1286 - 1286
  • [47] Missing HLA C Group 1 Ligands in Patients with AML and MDS Is Associated with Reduced Risk of Relapse and Improved Survival after Allogeneic STEM CELL Transplantation (SCT) with Fludarabine and Treosulfan Reduced Toxicity Conditioning
    Shimoni, Avichai
    Bemardi, Massimo
    Yerushalmi, Ronit
    Peccatori, Iacopo
    Shem-Tov, Noga
    Lo Russo, Alessandro
    Volchek, Yulia
    Bonini, Maria Chiara
    Nagler, Arnon
    Ciceri, Fabio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S280 - S281
  • [48] Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) For Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Following Intravenous Busulfan/Fludarabine Based Conditioning: Outcomes and Monocyte Chemo-Attractant Protein-1(MCP-1) As a Predictive Marker Of Relapse
    Matar, Abraham
    Solh, Melhem M.
    Copik, Alicja J.
    Litherland, Sally
    OliverasAlmodovar, Alvin
    Rathmann, Kristin
    Khaled, Yasser
    BLOOD, 2013, 122 (21)
  • [49] Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
    Sebastian Giebel
    Myriam Labopin
    Malgorzata Sobczyk-Kruszelnicka
    Matthias Stelljes
    Jenny L. Byrne
    Nathalie Fegueux
    Dietrich W. Beelen
    Montserrat Rovira
    Alexandros Spyridonidis
    Didier Blaise
    Martin Bornhäuser
    Ihsan Karadogan
    Bipin N. Savani
    Arnon Nagler
    Mohamad Mohty
    Bone Marrow Transplantation, 2021, 56 : 481 - 491
  • [50] AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION WITH PLERIXAFOR (P) PLUS G-CSF (G) IN PATIENTS <65 AND ≥65 YEARS OF AGE IN FRONTLINE AND MOBILIZATION FAILURE SETTINGS FOR MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL)
    Schriber, J.
    Kadota, R. P.
    Llanos, S. R.
    Micallef, I.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S217 - S218
12345